CRISPR Therapeutics (NASDAQ:CRSP) PT Lowered to $84.00 at Citigroup

CRISPR Therapeutics (NASDAQ:CRSP) had its price objective lowered by Citigroup from $89.00 to $84.00 in a research report report published on Thursday, Benzinga reports. Citigroup currently has a buy rating on the stock.

Several other analysts have also recently commented on CRSP. Robert W. Baird increased their target price on CRISPR Therapeutics from $46.00 to $52.00 and gave the stock a neutral rating in a report on Thursday, May 9th. Barclays lowered their price objective on shares of CRISPR Therapeutics from $80.00 to $67.00 and set an equal weight rating for the company in a research report on Thursday, May 9th. TheStreet upgraded shares of CRISPR Therapeutics from a d+ rating to a c rating in a research report on Friday, February 23rd. JMP Securities reissued a market outperform rating and issued a $86.00 price target on shares of CRISPR Therapeutics in a report on Thursday, May 9th. Finally, Mizuho upped their price objective on CRISPR Therapeutics from $82.00 to $99.00 and gave the stock a buy rating in a report on Wednesday, March 6th. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of Hold and a consensus target price of $73.57.

CRISPR Therapeutics Trading Down 0.9 %

Shares of CRISPR Therapeutics stock opened at $55.24 on Thursday. CRISPR Therapeutics has a 1-year low of $37.55 and a 1-year high of $91.10. The firm’s 50-day moving average price is $60.23 and its two-hundred day moving average price is $65.54. The stock has a market capitalization of $4.69 billion, a price-to-earnings ratio of -20.31 and a beta of 1.80.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Wednesday, May 8th. The company reported ($1.43) EPS for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.08). The company had revenue of $0.50 million during the quarter, compared to analyst estimates of $25.53 million. During the same quarter in the previous year, the business posted ($0.67) EPS. CRISPR Therapeutics’s revenue was down 99.5% compared to the same quarter last year. As a group, equities research analysts predict that CRISPR Therapeutics will post -5.64 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Samarth Kulkarni sold 19,582 shares of the company’s stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $59.91, for a total value of $1,173,157.62. Following the completion of the sale, the chief executive officer now directly owns 208,122 shares of the company’s stock, valued at approximately $12,468,589.02. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, CFO Raju Prasad sold 3,524 shares of the firm’s stock in a transaction on Friday, March 15th. The stock was sold at an average price of $72.69, for a total transaction of $256,159.56. Following the sale, the chief financial officer now owns 6,476 shares of the company’s stock, valued at approximately $470,740.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Samarth Kulkarni sold 19,582 shares of the business’s stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $59.91, for a total value of $1,173,157.62. Following the completion of the transaction, the chief executive officer now directly owns 208,122 shares of the company’s stock, valued at $12,468,589.02. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 55,709 shares of company stock worth $3,865,228. Insiders own 4.10% of the company’s stock.

Institutional Investors Weigh In On CRISPR Therapeutics

A number of hedge funds have recently modified their holdings of CRSP. Cetera Advisors LLC acquired a new stake in CRISPR Therapeutics during the 1st quarter worth approximately $334,000. Cetera Investment Advisers raised its holdings in shares of CRISPR Therapeutics by 451.3% during the first quarter. Cetera Investment Advisers now owns 34,100 shares of the company’s stock worth $2,324,000 after acquiring an additional 27,915 shares during the period. Virtu Financial LLC lifted its position in CRISPR Therapeutics by 106.5% in the 1st quarter. Virtu Financial LLC now owns 63,742 shares of the company’s stock valued at $4,345,000 after acquiring an additional 32,880 shares in the last quarter. EMC Capital Management acquired a new position in CRISPR Therapeutics in the 1st quarter worth $66,000. Finally, California State Teachers Retirement System increased its holdings in CRISPR Therapeutics by 1.1% during the 1st quarter. California State Teachers Retirement System now owns 67,901 shares of the company’s stock worth $4,628,000 after purchasing an additional 710 shares in the last quarter. Institutional investors and hedge funds own 69.20% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.